Pivotal Trial Finds That Imbruvica Shows Benefit in CLL and SLL Imbruvica (ibrutinib) reduced the risk of progression or death by 88 percent compared to chlorambucil in patients with chronic lymphocytic l... 297 0Like
Transplant Is a Mainstay in Hematologic Cancers, Expert Says Even as the US Food and Drug Administration (FDA) approved new agents for multiple myeloma and some lymphomas, stem cell transplant remains ... 231 0Like
